Using Simulation for AIDS Policy Modeling: Benefits for HIV/AIDS Prevention Policy Makers in Vienna, Austria

In spite of advanced therapies and the success of additional prevention programs, the HIV/AIDS epidemic still remains a challenge. Our paper refers academics, health care managers, and policy makers to the relevance of AIDS policy simulators in better decision-making. By highlighting the types of decisions AIDS policy models can support, we demonstrate the strategic role of AIDS policy simulators for the efficient and effective planning of scarce resources to fight the epidemic. For each type of decision, we then review exemplary AIDS policy simulators that have helped policy makers make better decisions. Finally, we present the benefits of an AIDS policy simulator for HIV/AIDS prevention policy makers in Vienna, Austria.

[1]  M. Weinstein,et al.  The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. , 1996, JAMA.

[2]  A. Salzberg,et al.  A multiperiod compartmental model of the HIV pandemic in the United States , 1991 .

[3]  Margaret L. Brandeau,et al.  Methadone Maintenance and HIV Prevention: A Cost-Effectiveness Analysis , 2000 .

[4]  Giuseppe Schinaia,et al.  Estimating the Size of the HIV/AIDS Epidemic: Complementary Use of the Empirical Bayesian Back-Calculation and the Mover-Stayer Model for Gathering the Largest Amount of Information , 1998, Simul..

[5]  M. Brandeau,et al.  AIDS Policy Modeling for the 21st Century: An Overview of Key Issues , 2001, Health care management science.

[6]  D K Owens,et al.  Screening women of childbearing age for human immunodeficiency virus. A cost-benefit analysis. , 1992, Archives of internal medicine.

[7]  James G. Anderson,et al.  HIV Screening and Treatment of Pregnant Women and Their Newborns: A Simulation-Based Analysis , 1998, Simul..

[8]  I. Romieu,et al.  Modeling the AIDS epidemic in Mexico City. , 1991, Human biology.

[9]  E. Ruitenberg.  AIDS up to the year 2000: epidemiological, sociocultural and economic scenario analysis for the Netherlands. , 1992 .

[10]  H. Pollack.  Can we protect drug users from hepatitis C? , 2001, Journal of policy analysis and management : [the journal of the Association for Public Policy Analysis and Management].

[11]  Douglas K Owens,et al.  Screening Women of Childbearing Age for Human Immunodeficiency Virus: A Model-Based Policy Analysis , 1993 .

[12]  D. Ward,et al.  Costs of HIV+/AIDS at CD4+ counts disease stages based on treatment protocols. , 1996, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[13]  D. Macrae,et al.  Policies for curbing the HIV epidemic in the United States: Implications of a simulation model , 1993 .

[14]  Jonathan P. Caulkins,et al.  Optimal Control of Drug Epidemics: Prevent and Treat--But Not at the Same Time?: Prevent and Treat--But Not at the Same Time? , 2000 .

[15]  Brian Dangerfield,et al.  A role for system dynamics in modelling the spread of AIDS , 1989 .

[16]  Combined antiviral treatment in HIV infection. Is it value for money? , 1999, Public health.

[17]  M. Fowler,et al.  Update on perinatal HIV transmission. , 2000, Pediatric clinics of North America.

[18]  R. Anderson,et al.  Modeling the impact and cost‐effectiveness of HIV prevention efforts , 1994, AIDS.

[19]  Margaret L. Brandeau,et al.  OR Modeling and AIDS Policy: From Theory to Practice , 1998, Interfaces.

[20]  D. Kault.  Modelling AIDS reduction strategies. , 1995, International journal of epidemiology.

[21]  Tammy O. Tengs,et al.  Five-hundred life-saving interventions and their cost-effectiveness. , 1995, Risk analysis : an official publication of the Society for Risk Analysis.

[22]  J. Esparza,et al.  Accelerating the development and future availability of HIV-1 vaccines: why, when, where, and how? , 2000, The Lancet.

[23]  Kurt Heidenberger,et al.  Taxonomies in the strategic management of health technology: the case of multiperiod compartmental HIV/AIDS policy models , 1998 .

[24]  T. Sexton,et al.  Long-Term Projections of the AIDS Epidemic , 1991 .

[25]  M. Ainsworth.  Confronting AIDS : public priorities in a global epidemic , 1997 .

[26]  K Heidenberger,et al.  Strategic decision support in preventive health care. , 1992, Socio-economic planning sciences.

[27]  M C Weinstein,et al.  The cost-effectiveness of preventing AIDS-related opportunistic infections. , 1998, JAMA.

[28]  Kenneth A. Freedberg,et al.  A Monte Carlo Simulation of Advanced HIV Disease , 1998, Medical decision making : an international journal of the Society for Medical Decision Making.

[29]  An Overview of Economic Evaluation Methodologies and Selected Issues in Methods Standardization , 1998 .

[30]  David R. Holtgrave,et al.  Assessing the Cost-Effectiveness of HIV Prevention Interventions , 1998 .

[31]  E H Kaplan,et al.  A circulation theory of needle exchange. , 1994, AIDS.

[32]  H. Hethcote,et al.  Modeling HIV Transmission and AIDS in the United States , 1992 .

[33]  Edward H. Kaplan,et al.  Allocating HIV prevention resources , 1998 .

[34]  P. Vernazza,et al.  Quantification of HIV in semen: correlation with antiviral treatment and immune status , 1997, AIDS.

[35]  C. Corbett,et al.  HIV infection in adults: a therapeutic update. , 1999, The American journal of managed care.

[36]  A. K. Shahani,et al.  HIV and AIDS patient care: operational models for resource planning , 1994 .

[37]  Harvey V. Fineberg,et al.  No Time To Lose: Getting More from HIV Prevention , 2001 .

[38]  David R. Holtgrave,et al.  Cost-effectiveness of post-exposure prophylaxis following sexual exposure to HIV. , 1998 .

[39]  D K Owens,et al.  An Analysis of Optimal Resource Allocation for Prevention of Infection with Human Immunodeficiency Virus (HIV) in Injection Drug Users and Non-Users , 1999, Medical decision making : an international journal of the Society for Medical Decision Making.

[40]  Giuseppe Schinaia,et al.  The Mover-Stayer Model for the HIV/AIDS Epidemic in Action , 1998, Interfaces.

[41]  K. Freedberg,et al.  The Cost-Effectiveness of Fluconazole Prophylaxis against Primary Systemic Fungal Infections in AIDS Patients , 1997, Medical decision making : an international journal of the Society for Medical Decision Making.

[42]  Travis C. Porco,et al.  Designing HIV Vaccination Policies: Subtypes and Cross-Immunity , 1998, Interfaces.

[43]  John Stover,et al.  Simulating the Control of a Heterosexual HIV Epidemic in a Severely Affected East African City , 1998, Interfaces.

[44]  J. J. Henning,et al.  Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents, January 28, 2000 , 1998, HIV clinical trials.

[45]  F J Hellinger,et al.  The lifetime cost of treating a person with HIV. , 1993, JAMA.

[46]  J. Caulkins,et al.  A dynamic model of drug initiation: implications for treatment and drug control. , 1999, Mathematical biosciences.

[47]  Sake J. De Vlas,et al.  STDSIM: A Microsimulation Model for Decision Support in STD Control , 1998, Interfaces.

[48]  M. Weinstein,et al.  Economic Evaluation of HIV Testing Among Intravenous Drug Users: An Analytic Framework and Its Application to Italy , 1996, International Journal of Technology Assessment in Health Care.

[49]  Margaret L. Brandeau,et al.  The Effects of Protease Inhibitors on the Spread of HIV and the Development of Drug-Resistant HIV Strains: A Simulation Study , 1998, Simul..

[50]  Kenneth A. Freedberg,et al.  The Cost-Effectiveness of Preventing Cytomegalovirus Disease in AIDS Patients , 1998, Interfaces.

[51]  H V Fineberg,et al.  Bleach programs for preventing AIDS among i.v. drug users: modeling the impact of HIV prevalence. , 1991, American journal of public health.

[52]  Manuel Battegay,et al.  Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study , 1997, BMJ.

[53]  B. Dangerfield,et al.  Model-based scenarios for the epidemiology of HIV/AIDS: the consequences of highly active antiretroviral therapy , 2001 .

[54]  B. Dangerfield,et al.  Modelling the Epidemiological Consequences of HIV Infection and AIDS: A Contribution from Operational Research , 1990 .

[55]  M. Brandeau,et al.  Effect of Relapse to High-Risk Behavior on the Costs and Benefits of a Program to Screen Women for Human Immunodeficiency Virus , 1998 .

[56]  Objectives for a system of health care delivery for HIV infected people. , 1989, Socio-economic planning sciences.

[57]  Kurt Heidenberger,et al.  Strategic investment in preventive health care: Quantitative modelling for programme selection and resource allocation , 1996 .

[58]  C. Rossi.  Estimating the prevalence of injecting drug users on the basis of Markov models of the HIV/AIDS epidemic: applications to Italian data , 1999, Health care management science.

[59]  J. Homer,et al.  A Model of HIV Transmission through Needle Sharing , 1991 .

[60]  Kurt Heidenberger,et al.  A system dynamics model for AIDS policy support in Tanzania , 1993 .

[61]  M. Brandeau,et al.  The cost effectiveness of voluntary prenatal and routine newborn HIV screening in the United States. , 2000 .

[62]  David J. Ahlgren,et al.  Dynamic models of the AIDS epidemic , 1990, Simul..

[63]  M. Weinstein,et al.  Recommendations of the Panel on Cost-effectiveness in Health and Medicine. , 1996, JAMA.

[64]  Marion S. Rauner,et al.  Resource allocation for HIV/AIDS control programs: a model-based policy analysis , 2002, OR Spectr..

[65]  G. Scott,et al.  MEDICAL MANAGEMENT OF HIV DISEASE IN CHILDREN , 2000, Pediatric Clinics of North America.

[66]  Douglas K Owens,et al.  A Policy Model of Human Immunodeficiency Virus Screening and Intervention , 1991 .

[67]  A. Perelson,et al.  Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. , 1999, The New England journal of medicine.

[68]  Ross D. Shachter,et al.  A Dynamic HIV-Transmission Model for Evaluating the Costs and Benefits of Vaccine Programs , 1998, Interfaces.

[69]  R. Coutinho.  HIV and hepatitis C among injecting drug users , 1998, BMJ.

[70]  E H Kaplan,et al.  Needles that kill: modeling human immunodeficiency virus transmission via shared drug injection equipment in shooting galleries. , 1989, Reviews of infectious diseases.

[71]  M L Brandeau,et al.  HIV transmission and the cost-effectiveness of methadone maintenance. , 2000, American journal of public health.

[72]  L D Xu.  A decision support system for AIDS intervention and prevention. , 1994, International journal of bio-medical computing.

[73]  H. Gershengorn,et al.  A tale of two futures: HIV and antiretroviral therapy in San Francisco. , 2000, Science.

[74]  N. Crofts,et al.  Methadone maintenance and hepatitis C virus infection among injecting drug users. , 1997, Addiction.

[75]  P. Vernazza,et al.  Potent antiretroviral treatment of HIV-infection results in suppression of the seminal shedding of HIV , 2000, AIDS.